Acusphere, Inc. Reports Q4 2008 Recent Business Highlights, Business Priorities and Financial Results

Acusphere, Inc. (ACUS:PK) reported financial results for the fourth quarter and year ended December 31, 2008, and commented on its business and progress to date. The Company continues to discuss its New Drug Application (NDA) with the U.S. Food & Drug Administration (FDA) for its lead product candidate, ImagifyTM (Perflubutane Polymer Microspheres) for Injectable Suspension following the receipt of FDA’s complete response letter in late February. Imagify is a Perfusion Stress Echo imaging agent targeted for use in detecting coronary artery disease. Recent Business Highlights Signed an agreement to terminate and transition the Company’s Collaboration, License and Supply Agreement for...

Want to see the full article?

• Purchase this article for only $3.00